The international guidelines for surveillance following the finding of a small tubular adenoma vary between no surveillance or colonoscopy at 5 or 10 years, whereas surveillance after an advanced adenoma is 3 years. Optimization of surveillance reduces the risk of colorectal cancer (CRC) with efficient use of colonoscopy resources. We assessed the risks of advanced colorectal neoplasia following a baseline finding of a small adenoma compared with advanced adenoma.
A retrospective audit was undertaken of patients enrolled in a CRC surveillance program, wherein regular colonoscopies and screening with faecal immunochemical test (FIT) were provided. Patients diagnosed with either small or advanced adenoma followed by at least one surveillance colonoscopy were included. Advanced adenoma included adenomas with features of villous change, size of at least 10 mm, high-grade dysplasia, three or more small tubular adenomas and traditional and sessile serrated adenomas. Subdistribution hazard ratios were calculated for advanced neoplasia (CRC or advanced adenoma).
Overall, 378 patients (62.6±11.2 years, 57.9% male) were included, with 44.2% diagnosed with small adenoma and 55.5% with advanced adenoma at baseline. The crude cumulative incidence of advanced neoplasia at first surveillance was 13.2 and 18.5% after small and advanced adenoma (P=0.16) (at 45.9 and 35.6 months, respectively), which became significant for advanced adenoma after adjustment (subdistribution hazard ratio=2.55, 95% confidence interval=1.49–4.35, P<001). A positive FIT was the only independent predictor of advanced neoplasia after a small adenoma at baseline colonoscopy (odds ratio=5.05, 95% confidence interval=1.27–20.02, P=0.02).
The risk of advanced neoplasia following a small adenoma was lower than that following an advanced adenoma, but was strongly predicted by a positive FIT. Reducing frequency of colonoscopy while providing regular FIT might be a more efficient use of resources for this population.
aBowel Health Service, Flinders Medical Centre
bFlinders Centre for Innovation in Cancer
cDepartment of Gastroenterology and Hepatology, Flinders Medical Centre
dFlinders Centre for Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Bedford Park
eDepartment of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Correspondence to Erin L. Symonds, PhD, Bowel Health Service, c/o Level 3 Flinders Centre for Innovation in Cancer, Flinders Drive, Bedford Park, SA 5042, Australia Tel: +61 88 404 2813; fax: +61 88 404 2665; e-mail: email@example.com
Received October 29, 2018
Accepted December 20, 2018